By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Moffitt Cancer Center and diagnostics service firm CvergenX announced today an exclusive worldwide licensing agreement covering CvergenX's radiation therapy technology platform called InterveneXRT.

In a statement, Moffitt said that its researchers have used gene expression analysis and system biology "to create a radio-sensitivity classification index for individual tumors."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.